City Therapeutics, a buzzy biotechnology startup working on new types of RNA interference therapies,

City Therapeutics 是一家备受关注的生物技术初创公司，致力于研发新型 RNA 干扰疗法，

secured $200 million

获得2亿美元资金

in an initial public offering on Thursday.

在周四的首次公开募股中。

City sold just over 11.1 million shares at $18 apiece, more than it had expected when setting projections earlier this week. It will begin trading on the

City以每股18美元的价格售出略超1,110万股，高于本周早先设定预测时的预期。它将于

Nasdaq on Friday

周五的纳斯达克

under the ticker symbol “CTY.”

股票代码为“CTY”。

Co-founded by longtime Alnylam Pharmaceuticals CEO John Maraganore, City is one of

由Alnylam Pharmaceuticals长期首席执行官John Maraganore联合创办的City是其中之一

many young companies

许多年轻的公司

aiming to take RNA interference technology — a way of silencing genes before they can make harmful proteins — in

旨在将RNA干扰技术——一种在基因产生有害蛋白质之前将其沉默的方法——应用于

new directions

新方向

. Though eight RNAi medicines have been approved by regulators, most are used to treat rare diseases and all are aimed at genetic targets in the liver.

尽管已有八种RNAi药物获得监管机构批准，但大多数用于罕见病的治疗，且全部针对肝脏中的遗传靶点。

Newer technical advances have emboldened companies to broaden RNAi’s reach. Some are focusing on more common conditions, while others are trying to send RNAi drugs into different tissue types, like the brain or lungs.

较新的技术进步使公司更有信心扩大RNAi的应用范围。一些公司正专注于更常见的疾病，而另一些公司则试图将RNAi药物递送至不同的组织类型，如大脑或肺部。

City is working on a mix of both. The top three drugs in its pipeline, for instance, are directed at liver targets. Yet they’re for a combination of chronic conditions — like clotting disorders and anemia — and degenerative eye diseases.

该公司正致力于双管齐下。例如，其研发管线中排名前三的药物均针对肝脏靶点，但旨在治疗慢性病症（如凝血障碍和贫血）与退行性眼病的组合疾病。

The company’s most advanced candidate is dubbed CITY-FXI and aims at the blood-clotting protein Factor XI. Like other

该公司最先进的候选药物名为CITY-FXI，靶向凝血蛋白因子XI。与其他

Factor XI-targeting drugs

靶向因子XI的药物

in development

开发中

, City’s prospect is designed to prevent “thromboembolic” diseases, when blood clots form, spring loose and cause harm. It’s also supposed to lower the risk of bleeds, a safety hazard associated with existing medications.

City’s 候选药物旨在预防“血栓栓塞性”疾病，即当血凝块形成、脱落并造成危害时。它还应该降低出血风险，这是现有药物相关的一个安全隐患。

City plans to develop the therapy in multiple indications, including secondary stroke prevention, atrial fibrillation and cancer-associated thrombosis. Phase 1 testing has shown an ability to drop Factor XI levels by as much as 85%. The company’s first Phase 2 trial, expected next year, will involve people who have a higher risk of a postoperative clot following a knee replacement..

City 计划在多种适应症中开发该疗法，包括二级卒中预防、心房颤动和癌症相关血栓形成。I 期试验显示，该疗法能够将 XI 因子水平降低高达 85%。该公司预计明年开展的首项 II 期临床试验将招募膝关节置换术后血栓风险较高的患者。

The company’s second most advanced candidate is for Stargardt disease, a genetic eye condition

该公司第二先进的候选药物针对的是斯塔加特病，一种遗传性眼部疾病

several

几个

biotechs

生物技术公司

are targeting

正在针对

with oral drugs, gene therapies and other approaches. Called CITY-RBP4, it mutes a gene that produces “RBP4,” a protein that shepherds vitamin A to the eye. It’ll enter a Phase 1 clinical trial later this year, and should produce results in 2027.

包括口服药物、基因疗法和其他方法。该疗法名为CITY-RBP4，通过抑制产生“RBP4”的基因发挥作用，RBP4是一种将维生素A输送至眼部的蛋白质。它将于今年晚些时候进入I期临床试验，并有望在2027年公布结果。

City is exploring CITY-RBP4’s use in other eye diseases, including geographic atrophy, too.

City 也在探索 CITY-RBP4 在其他眼部疾病（包括地图样萎缩）中的应用。

A third City program is for a particularly common form of anemia that occurs when long-term illnesses trigger chronic inflammation. This “anemia of chronic disease” affects over five million people in the U.S., the company said. An early-stage study is coming in 2027. City may eventually test it in other disorders where anemia is prevalent, such as chronic kidney disease..

City的第三个项目针对的是由长期疾病引发慢性炎症所导致的一种尤为常见的贫血形式。该公司表示，这种“慢性病性贫血”在美国影响着超过500万人。一项早期阶段的研究将于2027年启动。City最终可能会在其他贫血高发的疾病（如慢性肾病）中对该疗法进行测试。

Beyond those therapies is earlier research meant to expand the reach of RNAi treatments “across new tissues, targets and disease areas,” City said in its filing. Partnerships with

City 在其申报文件中表示，除了这些疗法之外，早期研究旨在将 RNAi 治疗的应用范围“扩展到新的组织、靶点和疾病领域”。与

Bausch + Lomb

博士伦

and

和

Biogen

渤健

are part of that effort. So are two programs built around tiny, synthetic RNAs that City believes to have certain advantages over traditional RNAi approaches.

是这一努力的一部分。此外，还有两个围绕微小合成RNA构建的项目，City认为这些RNA相较于传统的RNAi方法具有某些优势。

Prior to its IPO, City raised about $239 million in venture funding from Arch Venture Partners, Fidelity Management & Research and Invus, among others.

在首次公开募股（IPO）之前，City 从 Arch Venture Partners、富达管理与研究公司（Fidelity Management & Research）以及 Invus 等机构筹集了约 2.39 亿美元的风险投资。